$TELA Bio(TELA.US)$ NEWS TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures TELA Bio, Inc. announces the U.S. commercial launch of OviTex IHR, a reinforced tissue matrix for inguinal hernia repair. The product offers trocar-compatibility for laparoscopic and robotic procedures, with three configurations available. OviTex has a strong clinical track record with low recurrence rates and high pati...
Despite TELA Bio's high revenue growth, its P/S ratio barely aligns with industry median, indicating public skepticism about future growth. Its current stock price could be attractive, yet it shows two risk signs.